Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection

Virulence

Volumn 2, Issue 4, 2011, Pages 348-355

  Lewis, Russell E ^a,b   Liao, Guangling ^a   Wang, Weiqun ^a   Prince, Randall A ^a,b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antifungal; Aspergillosis; Breakthrough; Mucormycosis; Selection; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CORTICOSTEROID; MICAFUNGIN; SODIUM CHLORIDE; VORICONAZOLE; ANTIFUNGAL AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; FUNGAL GENE; IN VITRO STUDY; INOCULATION; LUNG MYCOSIS; MIXED INFECTION; MOUSE; MUCORMYCOSIS; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RHIZOPUS ORYZAE; SPORANGIOSPORE; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECT; FEMALE; GENETICS; HUMAN; MICROBIOLOGY; PATHOGENICITY; PHYSIOLOGY; PNEUMONIA; RHIZOPUS; VIRULENCE;

ANIMALIA; ASPERGILLUS; ASPERGILLUS FUMIGATUS; FUNGI; MUCORALES; MUS; RHIZOPUS ORYZAE;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MUCORMYCOSIS; PNEUMONIA; PYRIMIDINES; RHIZOPUS; TRIAZOLES; VIRULENCE;

EID: 85046979740     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.2.4.17074     Document Type: Article

References (34)

1. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265-73; PMID:19115967; DOI:10.1086/595846.
2. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091-100; PMID:20218877; DOI:10.1086/651263.
3. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950-2; PMID:14985500; DOI:10.1056/ NEJM200402263500923.
4. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, Bartlet LA, Kilborn SH, Hoth PL, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39:584-7; PMID:15356827; DOI:10.1086/422723.
5. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39:743-6; PMID:15356792; DOI:10.1086/423274.
6. Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40:451-6; PMID:17589527; DOI:10.1038/sj.bmt.1705754.
7. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al. Zygomycosis in a tertiarycare cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350-60; PMID:15776383; DOI:10.1086/428780.
8. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: ASM Press 2007.
9. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116:5111-8; PMID:20826719; DOI:10.1182/blood-2010-02-268151.
10. Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clin Microbiol Infect 2009; 15:93-7; PMID:19754766; DOI:10.1111/j.1469-0691.2009.02988.x.
11. Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 2009; 199:1399-406; PMID:19358672; DOI:10.1086/597615.
12. Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005; 73:494-503; PMID:15618189; DOI:10.1128/ IAI.73.1.494-503.2005.
13. Bowman JC, Abruzzo GK, Anderson JW, Flattery AM, Gill CJ, Pikounis VB, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: Demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45:3474-81; PMID:11709327; DOI:10.1128/AAC.45.12.3474-81.2001.
14. Ibrahim AS, Bowman JC, Avanessian V, Brown K, Spellberg B, Edwards JE Jr, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49:721-7; PMID:15673756; DOI:10.1128/AAC.49.2.721-7.2005.
15. Sugar AM, Liu XP. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol 2000; 38:209-12; PMID:10892988.
16. Graybill JR, Najvar LK, Gonzalez GM, Hernandez S, Bocanegra R. Improving the mouse model for studying the efficacy of voriconazole. J Antimicrob Chemother 2003; 51:1373-6; PMID:12746374; DOI:10.1093/ jac/dkg261.
17. Takemoto K, Yamamoto Y, Ueda Y, Kanazawa K, Yoshida K, Niki Y. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model. Chemotherapy 2009; 55:105-13; PMID:19151551; DOI:10.1159/000194661.
18. Pascual A, Nieth V, Calandra T, Bille J, Bolay S, Decosterd LA, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007; 51:137-43; PMID:17088483; DOI:10.1128/AAC.00957-06.
19. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in pateints with invasive mycoses improves safety and efficacy outcomes. Clin Infect Dis 2008; 46:201-11; PMID:18171251; DOI:10.1086/524669.
20. Chamilos G, Lewis RE, Hu J, Xiao L, Zal T, Gilliet M, et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci USA 2008; 105:9367-72; PMID:18583479; DOI:10.1073/pnas.0709578105.
21. Spellberg B, Fu Y, Edwards JE Jr, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49:830-2; PMID:15673781; DOI:10.1128/AAC.49.2.830-2.2005.
22. Anderson JB. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 2005; 3:547-56; PMID:15953931; DOI:10.1038/ nrmicro1179.
23. Ibrahim AS, Gebremariam T, Lin L, Luo G, Husseiny MI, Skory CD, et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol 2010; 77:587-604; PMID:20545847; DOI:10.1111/j.1365-2958.2010.07234.x.
24. Liu M, Spellberg B, Phan QT, Fu Y, Fu Y, Lee AS, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010; 120:1914-24; PMID:20484814; DOI:10.1172/JCI42164.
25. Wu T, Wright K, Hurst SF, Morrison CJ. Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole. Antimicrob Agents Chemother 2000; 44:1200-8; PMID:10770752; DOI:10.1128/AAC.44.5.1200-8.2000.
26. Barelle CJ, Duncan VM, Brown AJ, Gow NA, Odds FC. Azole antifungals induce upregulation of SAP4, SAP5 and SAP6 secreted proteinase genes in filamentous Candida albicans cells in vitro and in vivo. J Antimicrob Chemother 2008; 61:315-22; PMID:18033783; DOI:10.1093/jac/dkm456.
27. Sanguinetti M, Posteraro B, La Sorda M, Torelli R, Firoi B, Santangelo R, et al. Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans. Infect Immun 2006; 74:1352-9; PMID:16428784; DOI:10.1128/IAI.74.2.1352-9.2006.
28. Ma LJ, Ibrahim AS, Skory C, Grabherr MG, Burger G, Butler M, et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet 2009; 5:1000549; PMID:19578406; DOI:10.1371/journal.pgen.1000549.
29. Schoen C, Reichard U, Monod M, Kratzin HD, Ruchel R. Molecular cloning of an extracellular aspartic proteinase from Rhizopus microsporus and evidence for its expression during infection. Med Mycol 2002; 40:61-71; PMID:11860014.
30. Spreer A, Ruchel R, Reichard U. Characterization of an extracellular subtilisin protease of Rhizopus microsporus and evidence for its expression during invasive rhinoorbital mycosis. Med Mycol 2006; 44:723-31; PMID:17127629; DOI:10.1080/13693780600936399.
31. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982; 31:1109-14; PMID:6816646; DOI:10.2337/diabetes.31.12.1109.
32. Artis WM, Patrusky E, Rastinejad F, Duncan RL Jr. Fungistatic mechanism of human transferrin for Rhizopus oryzae and Trichophyton mentagrophytes: alternative to simple iron deprivation. Infect Immun 1983; 41:1269-78; PMID:6885162.
33. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard-Second Edition. Wayne, PA: Clinical and Laboratory Standards Institute 2008.
34. Wiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis RE. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50:469-73; PMID:16436698; DOI:10.1128/AAC.50.2.469-73.2006.